Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer

reatment for patients with recurrent ovarian cancer has been mainly based on systemic therapy. The role of secondary cytoreductive surgery is unclear. In this randomized trial (DESKTOP III), women with platinum sensitive relapsed ovarian cancer were assigned to either cytoreductive surgery followed by platinum based chemotherapy or chemotherapy alone. The study found that surgery followed by chemotherapy significantly improved median overall survival (53.7 months vs. 46.0 months) compared to chemotherapy alone, particularly in those who achieved complete resection. Quality of life remained similar between groups, and no perioperative mortality occurred.

reatment for patients with recurrent ovarian cancer has been mainly based on systemic therapy. The role of secondary cytoreductive surgery is unclear. In this randomized trial (DESKTOP III), women with platinum sensitive relapsed ovarian cancer were assigned to either cytoreductive surgery followed by platinum based chemotherapy or chemotherapy alone. The study found that surgery followed by chemotherapy significantly improved median overall survival (53.7 months vs. 46.0 months) compared to chemotherapy alone, particularly in those who achieved complete resection. Quality of life remained similar between groups, and no perioperative mortality occurred.